About Drupal 8
Have you ever felt that your website needs to be more personalized, integrated with cutting-edge technology to offer enhanced user experience?
Valuebound is one of those companies, which specifically help organizations in their path to digital transformation. We enhance digital experience for end users with tailored web applications.
Recent releases
|
How to Add Multiple MongoDB Database Support in Node.js Using Mongoose
Learn to add multiple MongoDB database support in Node.js with Mongoose. Discover defining connections, models, and using them in your app.
|
Cloud-Native vs. Cloud-Agnostic: Which Approach is Right for Your Business?
Discover the benefits of a cloud-native vs. cloud-agnostic approach for your business. Learn which approach can drive better ROI and see real-world examples. Contact Valuebound for expert guidance on…
|
Designing Highly Available Architectures with DynamoDB
Amazon DynamoDB is a fully managed NoSQL database service that offers a powerful solution for designing highly available architectures. This article delves into the intricacies of leveraging DynamoDB…
|
Introducing NodeMailer: Simplify Your Email Communications with Node.js
Discover NodeMailer, a powerful Node.js library that streamlines email communications. Send and receive emails effortlessly with Node.js
CASE STUDY
See all our work
How a Top Indian Pharma Brand Boosted HCP Engagement Using Tech-Led Omnichannel Marketing
India’s renowned pharmaceutical company, known for its strong presence in chronic therapy areas, was facing a growing disconnect with its most important audience: healthcare professionals.
How a Leading Indian Pharma Brand Expanded Reach Across Semi-Urban & Rural Regions
A leading pharmaceutical company in India, well known for its OTC presence and deep connection with mass-market audiences, was preparing to launch a public awareness campaign focused on maternal he
Driving Digital Engagement for a Chronic Care Program with Tech-Led Pharma Marketing
A leading pharmaceutical company in India, known for its chronic care drug portfolio, was preparing to launch a support program aimed at patients diagnosed with congestive heart failure (CHF).
